Last reviewed · How we verify

NCT06320314

Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins

Status unknown NA Last updated 20 March 2024
What this trial tests

NA trial testing tested product (2039125 03) in Hyperpigmentation in 60 participants. Status unknown.

Timeline
19 February 2024
Primary endpoint
22 May 2024
22 May 2024

Quick facts

Lead sponsorCosmetique Active International
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment60
Start date19 February 2024
Primary completion22 May 2024
Estimated completion22 May 2024
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Cosmetique Active International — full company profile →

Who can join

18 and older, any sex, with Hyperpigmentation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hyperpigmentation

Currently open trials in the same condition.

Other Cosmetique Active International trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06320314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing